Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol - A randomized study

Yu Hung Lin, Jiann-Loung Hwang, Kok Min Seow, Lee Wen Huang, Bih Chwen Hsieh, Chi Ruey Tzeng

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

This study evaluates the efficacy of a stimulation protocol with clomiphene citrate (CC)/human menopausal gonadotropin (hMG)/cetrorelix and its effects on oocyte quality and endometrium. One hundred and twenty couples with male-factor infertility who were about to undergo their first intracytoplasmic sperm injection cycles were randomized into two groups. Sixty women were stimulated with the CC/hMG/cetrorelix protocol (cetrorelix group) and 60 received the buserelin long protocol (buserelin group). Fewer oocytes were recovered in the cetrorelix group than in the buserelin group (mean ± standard deviation (SD): 11.1 ± 4.0 vs. 17.3 ± 5.8, p <0.001); however, the percentages of metaphase II, metaphase I and germinal vesicle oocytes were similar between the two groups. Serum estradiol level was significantly lower in the cetrorelix than in the buserelin group (mean ± SD: 2600.58 ± 1189.11 vs. 3293.46 ± 1221.49 pg/ml, p = 0.006), but the endometrial thickness was similar. The implantation rates (19.2% vs. 17.7%) and the pregnancy rates (41.7% vs. 40.0%) were similar between groups. The ampoules (mean ± SD: 18.9 ± 3.0 vs. 38.9 ± 12.2, p <0.001) and injections (mean ± SD: 6.8 ± 1.1 vs. 15.7 ± 3.1, p <0.001) of gonadotropin used were significantly lower in the cetrorelix group than in the buserelin group. No patients in either group developed a premature luteinizing hormone surge. The present study found no statistically significant difference between the two treatment modalities with regard to pregnancy rates.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalGynecological Endocrinology
Volume22
Issue number6
DOIs
Publication statusPublished - Jun 1 2006

Fingerprint

Buserelin
Menotropins
Clomiphene
Oocytes
Pregnancy Rate
Metaphase
Intracytoplasmic Sperm Injections
Male Infertility
Luteinizing Hormone
Endometrium
Gonadotropins
cetrorelix
Estradiol
Injections
Serum

Keywords

  • Buserelin
  • Cetrorelix
  • Clomiphene citrate
  • Gonadotropin-releasing hormone antagonist

ASJC Scopus subject areas

  • Endocrinology
  • Obstetrics and Gynaecology

Cite this

Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol - A randomized study. / Lin, Yu Hung; Hwang, Jiann-Loung; Seow, Kok Min; Huang, Lee Wen; Hsieh, Bih Chwen; Tzeng, Chi Ruey.

In: Gynecological Endocrinology, Vol. 22, No. 6, 01.06.2006, p. 297-302.

Research output: Contribution to journalArticle

Lin, Yu Hung ; Hwang, Jiann-Loung ; Seow, Kok Min ; Huang, Lee Wen ; Hsieh, Bih Chwen ; Tzeng, Chi Ruey. / Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol - A randomized study. In: Gynecological Endocrinology. 2006 ; Vol. 22, No. 6. pp. 297-302.
@article{6c5884e9e5dc44e493a2fdf971342c7b,
title = "Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol - A randomized study",
abstract = "This study evaluates the efficacy of a stimulation protocol with clomiphene citrate (CC)/human menopausal gonadotropin (hMG)/cetrorelix and its effects on oocyte quality and endometrium. One hundred and twenty couples with male-factor infertility who were about to undergo their first intracytoplasmic sperm injection cycles were randomized into two groups. Sixty women were stimulated with the CC/hMG/cetrorelix protocol (cetrorelix group) and 60 received the buserelin long protocol (buserelin group). Fewer oocytes were recovered in the cetrorelix group than in the buserelin group (mean ± standard deviation (SD): 11.1 ± 4.0 vs. 17.3 ± 5.8, p <0.001); however, the percentages of metaphase II, metaphase I and germinal vesicle oocytes were similar between the two groups. Serum estradiol level was significantly lower in the cetrorelix than in the buserelin group (mean ± SD: 2600.58 ± 1189.11 vs. 3293.46 ± 1221.49 pg/ml, p = 0.006), but the endometrial thickness was similar. The implantation rates (19.2{\%} vs. 17.7{\%}) and the pregnancy rates (41.7{\%} vs. 40.0{\%}) were similar between groups. The ampoules (mean ± SD: 18.9 ± 3.0 vs. 38.9 ± 12.2, p <0.001) and injections (mean ± SD: 6.8 ± 1.1 vs. 15.7 ± 3.1, p <0.001) of gonadotropin used were significantly lower in the cetrorelix group than in the buserelin group. No patients in either group developed a premature luteinizing hormone surge. The present study found no statistically significant difference between the two treatment modalities with regard to pregnancy rates.",
keywords = "Buserelin, Cetrorelix, Clomiphene citrate, Gonadotropin-releasing hormone antagonist",
author = "Lin, {Yu Hung} and Jiann-Loung Hwang and Seow, {Kok Min} and Huang, {Lee Wen} and Hsieh, {Bih Chwen} and Tzeng, {Chi Ruey}",
year = "2006",
month = "6",
day = "1",
doi = "10.1080/09513590600702733",
language = "English",
volume = "22",
pages = "297--302",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol - A randomized study

AU - Lin, Yu Hung

AU - Hwang, Jiann-Loung

AU - Seow, Kok Min

AU - Huang, Lee Wen

AU - Hsieh, Bih Chwen

AU - Tzeng, Chi Ruey

PY - 2006/6/1

Y1 - 2006/6/1

N2 - This study evaluates the efficacy of a stimulation protocol with clomiphene citrate (CC)/human menopausal gonadotropin (hMG)/cetrorelix and its effects on oocyte quality and endometrium. One hundred and twenty couples with male-factor infertility who were about to undergo their first intracytoplasmic sperm injection cycles were randomized into two groups. Sixty women were stimulated with the CC/hMG/cetrorelix protocol (cetrorelix group) and 60 received the buserelin long protocol (buserelin group). Fewer oocytes were recovered in the cetrorelix group than in the buserelin group (mean ± standard deviation (SD): 11.1 ± 4.0 vs. 17.3 ± 5.8, p <0.001); however, the percentages of metaphase II, metaphase I and germinal vesicle oocytes were similar between the two groups. Serum estradiol level was significantly lower in the cetrorelix than in the buserelin group (mean ± SD: 2600.58 ± 1189.11 vs. 3293.46 ± 1221.49 pg/ml, p = 0.006), but the endometrial thickness was similar. The implantation rates (19.2% vs. 17.7%) and the pregnancy rates (41.7% vs. 40.0%) were similar between groups. The ampoules (mean ± SD: 18.9 ± 3.0 vs. 38.9 ± 12.2, p <0.001) and injections (mean ± SD: 6.8 ± 1.1 vs. 15.7 ± 3.1, p <0.001) of gonadotropin used were significantly lower in the cetrorelix group than in the buserelin group. No patients in either group developed a premature luteinizing hormone surge. The present study found no statistically significant difference between the two treatment modalities with regard to pregnancy rates.

AB - This study evaluates the efficacy of a stimulation protocol with clomiphene citrate (CC)/human menopausal gonadotropin (hMG)/cetrorelix and its effects on oocyte quality and endometrium. One hundred and twenty couples with male-factor infertility who were about to undergo their first intracytoplasmic sperm injection cycles were randomized into two groups. Sixty women were stimulated with the CC/hMG/cetrorelix protocol (cetrorelix group) and 60 received the buserelin long protocol (buserelin group). Fewer oocytes were recovered in the cetrorelix group than in the buserelin group (mean ± standard deviation (SD): 11.1 ± 4.0 vs. 17.3 ± 5.8, p <0.001); however, the percentages of metaphase II, metaphase I and germinal vesicle oocytes were similar between the two groups. Serum estradiol level was significantly lower in the cetrorelix than in the buserelin group (mean ± SD: 2600.58 ± 1189.11 vs. 3293.46 ± 1221.49 pg/ml, p = 0.006), but the endometrial thickness was similar. The implantation rates (19.2% vs. 17.7%) and the pregnancy rates (41.7% vs. 40.0%) were similar between groups. The ampoules (mean ± SD: 18.9 ± 3.0 vs. 38.9 ± 12.2, p <0.001) and injections (mean ± SD: 6.8 ± 1.1 vs. 15.7 ± 3.1, p <0.001) of gonadotropin used were significantly lower in the cetrorelix group than in the buserelin group. No patients in either group developed a premature luteinizing hormone surge. The present study found no statistically significant difference between the two treatment modalities with regard to pregnancy rates.

KW - Buserelin

KW - Cetrorelix

KW - Clomiphene citrate

KW - Gonadotropin-releasing hormone antagonist

UR - http://www.scopus.com/inward/record.url?scp=33745381747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745381747&partnerID=8YFLogxK

U2 - 10.1080/09513590600702733

DO - 10.1080/09513590600702733

M3 - Article

VL - 22

SP - 297

EP - 302

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 6

ER -